232 related articles for article (PubMed ID: 19289643)
1. Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients.
Giannarelli C; Virdis A; De Negri F; Magagna A; Duranti E; Salvetti A; Taddei S
Circulation; 2009 Mar; 119(12):1625-33. PubMed ID: 19289643
[TBL] [Abstract][Full Text] [Related]
2. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients.
Taddei S; Versari D; Cipriano A; Ghiadoni L; Galetta F; Franzoni F; Magagna A; Virdis A; Salvetti A
J Am Coll Cardiol; 2006 Aug; 48(3):508-15. PubMed ID: 16875977
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.
Fichtlscherer S; Dimmeler S; Breuer S; Busse R; Zeiher AM; Fleming I
Circulation; 2004 Jan; 109(2):178-83. PubMed ID: 14662709
[TBL] [Abstract][Full Text] [Related]
4. Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole.
Passauer J; Büssemaker E; Lässig G; Pistrosch F; Fauler J; Gross P; Fleming I
Clin Sci (Lond); 2003 Oct; 105(4):513-8. PubMed ID: 12826020
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9.
Passauer J; Pistrosch F; Lässig G; Herbrig K; Büssemaker E; Gross P; Fleming I
Kidney Int; 2005 May; 67(5):1907-12. PubMed ID: 15840038
[TBL] [Abstract][Full Text] [Related]
6. The role of nitric oxide- and prostacyclin-independent vasodilatation in the human cutaneous microcirculation: effect of cytochrome P450 2C9 inhibition.
Lenasi H
Clin Physiol Funct Imaging; 2009 Jul; 29(4):263-70. PubMed ID: 19291087
[TBL] [Abstract][Full Text] [Related]
7. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway.
Brown NJ; Gainer JV; Murphey LJ; Vaughan DE
Circulation; 2000 Oct; 102(18):2190-6. PubMed ID: 11056091
[TBL] [Abstract][Full Text] [Related]
8. The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment.
Virdis A; Cetani F; Giannarelli C; Banti C; Ghiadoni L; Ambrogini E; Carrara D; Pinchera A; Taddei S; Bernini G; Marcocci C
J Clin Endocrinol Metab; 2010 Feb; 95(2):920-7. PubMed ID: 20022989
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide modulates tissue plasminogen activator release in normotensive subjects and hypertensive patients.
Giannarelli C; De Negri F; Virdis A; Ghiadoni L; Cipriano A; Magagna A; Taddei S; Salvetti A
Hypertension; 2007 Apr; 49(4):878-84. PubMed ID: 17339540
[TBL] [Abstract][Full Text] [Related]
10. Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm microcirculation in Type 2 diabetes: associations with blood pressure and HDL cholesterol.
Woodman RJ; Playford DA; Watts GF
Diabetes Res Clin Pract; 2006 Jan; 71(1):59-67. PubMed ID: 16029909
[TBL] [Abstract][Full Text] [Related]
11. Basal nitric oxide production is impaired in offspring of patients with essential hypertension.
McAllister AS; Atkinson AB; Johnston GD; Hadden DR; Bell PM; McCance DR
Clin Sci (Lond); 1999 Aug; 97(2):141-7. PubMed ID: 10409468
[TBL] [Abstract][Full Text] [Related]
12. [Vasodilator effects of bradykinin on the resistive circulation of the forearm of coronary patients].
Benacerraf S; Carville C; Sediame S; Belhassen L; Adnot S; Dubois-Randé JL
Arch Mal Coeur Vaiss; 2000 Sep; 93(9):1103-8. PubMed ID: 11055001
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of beta-adrenergic receptor-mediated venodilation in humans.
Schindler C; Dobrev D; Grossmann M; Francke K; Pittrow D; Kirch W
Clin Pharmacol Ther; 2004 Jan; 75(1):49-59. PubMed ID: 14749691
[TBL] [Abstract][Full Text] [Related]
14. Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease.
Ozkor MA; Murrow JR; Rahman AM; Kavtaradze N; Lin J; Manatunga A; Quyyumi AA
Circulation; 2011 May; 123(20):2244-53. PubMed ID: 21555712
[TBL] [Abstract][Full Text] [Related]
15. The contribution of nitric oxide and vasodilatory prostanoids to bradykinin-mediated vasodilation in Type 1 diabetes.
Wotherspoon F; Browne DL; Meeking DR; Allard SE; Munday LJ; Shaw KM; Cummings MH
Diabet Med; 2005 Jun; 22(6):697-702. PubMed ID: 15910619
[TBL] [Abstract][Full Text] [Related]
16. Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release.
Pretorius M; Brown NJ
J Pharmacol Exp Ther; 2010 Jan; 332(1):291-7. PubMed ID: 19841473
[TBL] [Abstract][Full Text] [Related]
17. Tissue-type plasminogen activator release in healthy subjects and hypertensive patients: relationship with beta-adrenergic receptors and the nitric oxide pathway.
Giannarelli C; Virdis A; De Negri F; Duranti E; Magagna A; Ghiadoni L; Salvetti A; Taddei S
Hypertension; 2008 Aug; 52(2):314-21. PubMed ID: 18574075
[TBL] [Abstract][Full Text] [Related]
18. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.
Tran D; Lowy A; Howes JB; Howes LG
Diabetes Obes Metab; 2005 May; 7(3):273-81. PubMed ID: 15811145
[TBL] [Abstract][Full Text] [Related]
19. Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension.
Bellien J; Iacob M; Remy-Jouet I; Lucas D; Monteil C; Gutierrez L; Vendeville C; Dreano Y; Mercier A; Thuillez C; Joannides R
Circulation; 2012 Mar; 125(10):1266-75. PubMed ID: 22412088
[TBL] [Abstract][Full Text] [Related]
20. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients.
Taddei S; Ghiadoni L; Virdis A; Buralli S; Salvetti A
Circulation; 1999 Sep; 100(13):1400-5. PubMed ID: 10500040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
